2023-509723-41-01招募中1 期
A Phase I Clinical Trial of CART cell therapy for refractory/ relapsed acute lymphoblastic leukemia with unmet needs in children, adolescents and young adults: feasibility and safety study (REALL_CART).
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2024年11月19日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- In this umbrella trial, we will determine in parallel within independent cohorts: 1- The safety and feasibility of autologous CART-19/22 in children, adolescents and young adults with a CD19+/- CD22+ relapse/ refractory disease for a r/r B-ALL. 2- The safety and feasibility of allogeneic CART-NKG2D T in children, adolescents and young adults with r/r T-ALL.
研究概览
简要总结
In this umbrella trial, we will determine in parallel within independent cohorts: 1- The safety and feasibility of autologous CART-19/22 in children, adolescents and young adults with a CD19+/- CD22+/- relapse/ refractory disease for a r/r B cell precursor ALL. 2- The safety and feasibility of allogeneic CART-NKG2D T in children, adolescents and young adults with r/r T-ALL.
研究设计
- 分配方式
- Non-randomized
- 主要目的
- Phase I, open label, prospective, single center, two-armed, non-randomized trial.
- 盲法
- None
入排标准
- 年龄范围
- 0 years 至 64 years（0-17 Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Age: Patients <30 years at diagnosis and/or relapse.
- •Lansky (age <16 years) or Karnofsky (age ≥16 years) score of 50 or greater.
- •Life expectancy greater than 12 weeks.
- •Absolute neutrophil count (ANC) ≥ 500/μL unless, in the opinion of the investigator, cytopenia is due to underlying leukemia and is potentially reversible with leukemia therapy.
- •Platelet count ≥ 50,000/μL unless, in the opinion of the investigator, cytopenia is due to underlying leukemia and is potentially reversible with leukemia therapy.
- •Absolute lymphocyte count ≥ 100/μL.
- •Adequate renal, hepatic, pulmonary, and cardiac function.
- •Adequate venous access and absence of contraindications for lymphoapheresis.
- •Patients with a seizure disorder may be enrolled if well controlled with anticonvulsants.
- •Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent.
- •Diagnosis: o ARM A: CD19+/- CD22+ B-ALL with relapsed or refractory disease not responding to conventional chemotherapy and with no other curative therapy available. Treatment with previous CART CD19 therapy is permitted, but is not mandatory. / o ARM B: T-ALL with relapsed or refractory disease not responding to conventional chemotherapy and with no other curative therapy available.
- •Patients diagnosed with ALL must be suitable for allogeneic HSCT and willing to proceed to transplant if the CART treatment induces complete remission and the investigator believes it is the best option.
- •For ARM B there must be a suitable haploidentical donor (following local SOP).
排除标准
- •Enrolled in another clinical trial in the previous 4 weeks.
- •Active infection requiring systemic medical therapy including clinically significant viral infection or uncontrolled viral reactivation of EBV, CMV, adenovirus, BK-virus, HHV-6 or Aspergillus.
- •Any of the following cardiac criteria: cardiac echocardiography with LVSF<30% or LVEF<40%; or clinically significant pericardial effusion.
- •Presence of CNS-3 disease or uncontrolled seizure disorder.
- •Active immunosuppressive therapy with the exception of prednisone 10 mg/day (or equivalent), within 7 days prior to enrolment.
- •GFR <30 ml/min or bilirubin >3 times the upper limit of normality (unless due to Gilbert's syndrome).
- •Any other condition that, in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the trial.
- •Pregnant or lactating women.
- •Sexually active patients must be willing to utilize one of the more effective birth control methods for at least 12 months after the infusion and until CAR-T cells are no longer present on two consecutive tests. Male partner should use a condom. Women of child-bearing potential are defined as all women physiologically capable of becoming pregnant. Highly effective contraception methods include, as defined by the CTFG recommendations (available at h t t p s : / / w w w . h m a . e u / f i l e a d m i n / d a t e i e n / H u m a n _ M e d i c i n e s / 0 1 -About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf): o Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) o Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) o Intrauterine device (IUD) o Intrauterine hormone-releasing system o Bilateral tubal occlusion o Vasectomized partner (provided that partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success) o Sexual abstinence (only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject). Sexually active males should use a condom during intercourse for at least 12 months after the infusion and until CAR-T cells are no longer present on two consecutive tests.
结局指标
主要结局
In this umbrella trial, we will determine in parallel within independent cohorts: 1- The safety and feasibility of autologous CART-19/22 in children, adolescents and young adults with a CD19+/- CD22+ relapse/ refractory disease for a r/r B-ALL. 2- The safety and feasibility of allogeneic CART-NKG2D T in children, adolescents and young adults with r/r T-ALL.
In this umbrella trial, we will determine in parallel within independent cohorts: 1- The safety and feasibility of autologous CART-19/22 in children, adolescents and young adults with a CD19+/- CD22+ relapse/ refractory disease for a r/r B-ALL. 2- The safety and feasibility of allogeneic CART-NKG2D T in children, adolescents and young adults with r/r T-ALL.
次要结局
- Expression of CD19/CD22 and NKG2DL on primary B- or T- cell ALL, respectively.
- Persistence of CART19/22 and CARTs-NKG2D cells in patients’ samples (peripheral blood, bone marrow, cerebrospinal fluid).
- Peripheral blood cytokine profile from the patients’ serum.
- Identify the DNA methylation profile of NKG2DL (MICA, MICB AND ULBPs 1-3) in primary T-cell malignancies’ samples.
- Evaluate the presence of soluble NKG2DL and ANTI-MICA and ANTI-MICB antibodies in the serum of patients under CART-NKG2D therapy.
- Overall rate response in both arms.
研究者
Dr. Antonio Pérez Martínez
Scientific
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase I Clinical Trial of CART cell therapy for refractory/ relapsed acute lymphoblastic leukemia with unmet needs in children, adolescents and young adults: feasibility and safety study (REALL_CART)Refractory/ relapsed acute lymphoblastic leukemia in children, adolescents and young adults.MedDRA version: 20.0Level: LLTClassification code: 10024338Term: Leukemia lymphoblastic acute Class: 10029104CTIS2023-509723-41-00Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz10
Unknown
早期 1 期
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT04626752Hebei Senlang Biotechnology Inc., Ltd.50
招募中
1 期
Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young AdultsPrecursor Cell Lymphoblastic Leukemia-LymphomaNCT06709469Instituto de Investigación Hospital Universitario La Paz10
进行中（未招募）
1 期
CART123 + Ruxolitinib in Relapsed/Refractory AMLRelapsed AMLRefractory AMLNCT06768476University of Pennsylvania12
尚未招募
早期 1 期
First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive LymphomaRefractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin LymphomaNCT06097455Fundacion Clinic per a la Recerca Biomédica40